


Am N 5
10
15
20


CLAIMS

1. A method of treating undesired angiogenesis in a human or animal comprising the step of administering to the human or animal with the undesired angiogenesis a composition comprising an effective amount of an angiogenesis-inhibiting compound selected from the group consisting of the following compounds:



In the above formulae A), B), and C), R₁, R₂, R₃ and R₄ can be selected from: -H; -OH; =O, straight chained and branched alkanes, alkenes, alkynes; cyclic alkanes, alkenes, and alkynes; combinations of cyclic and acyclic alkanes, alkenes, and alkynes; alcohol, aldehyde, ketone, carboxylic acid, ester, or ether moieties in combination with acyclic, cyclic, or combination

acyclic/cyclic moieties; aza; amino; $-XO_n$ or $-O-XO_n$, [where $X=N$ and $n=2$; $X=S$ and $n=2$ or 3 ; or $X=P$ and $n=1-3$]; and halogens; R_5 , R_6 , R_7 , and R_8 are each independently selected from:




5


or $-O-$ where Y is optional and is the same as defined above for R_1 ; and R_{10} is the same as defined above for R_1 , or (where Y is absent) R_{10} is $=O$; and R_9 is a moiety having formula D), E), F), G) or H):

10


D)




F)



E)




G)



15

where each of R_{11} - R_{17} is (independently) the same as defined above for R_5 ;

H)




where R_{18} , R_{19} and R_{20} are, independently selected from

~~$-H, CH_3, -C(=O)OH, -C(=O)-NH_2, -(CH_2)_n-C(=O)OH, or -(CH_2)_n-C(=O)-NH_2,$~~

and $n=1$ to 4.

2. The method of claim 1, wherein the compound has the following formula:



and R₅ and R₆ are selected from the group consisting of

$-CH_2$, $-CHOH$, and $-CO$

and in which R₉ has formula F) or H), and R₁₄ and R₁₆ are selected from the group consisting of,


$>CH_2$, $>CHOH$, or $-C(=O)-R_{21}$; and R₁₅ and is -O-, or $-N-$,

where R₂₁ is -H, -CH₃, or -OH.

3. The method of claim 1, wherein the compound is thalidomide.

4. The method of claim 1, wherein the compound is a thalidomide metabolite or hydrolysis product.

5. The method of Claim 1, wherein the compound is selected from the group consisting of the following compounds:



10 6. The method of claim 1, wherein the compound is selected from the group consisting of N-phthaloyl-DL-glutamic acid (PGA) and N-phthaloyl-DL-glutamine anhydride.

15 7. The method of claim 1; wherein the compound is EM-12.

20 8. The method of claim 1, wherein the compound is selected from the group of compounds shown in Figures 1 through 3.

25 9. The method of Claim 1, wherein the composition further comprises an epoxide hydrolase inhibitor.

10. The method of Claim 1, wherein the undesired angiogenesis is associated with retinal/choroidal neovascularization.

5

11. The method of Claim 10, wherein the retinal/choroidal newvascularization is associated with diabetic retinopathy.

10


15

12. The method of Claim 10, wherein the retinal/choroidal newvascularization is associated with macular degeneration.

20

13. The method of Claim 1, wherein the undesired angiogenesis is associated with corneal neovascularization.

5 14. A method of treating undesired angiogenesis in an human or animal comprising the step of administering to the human or animal with the undesired angiogenesis a composition comprising an effective amount of an angiogenesis-inhibiting compound selected from the group consisting of the following compounds:




10 where R_{22} and R_{23} are (independently), -H, -F, -Cl, -Br, -I, -CH₃, or -CH₂-CH₃; and R_{24} is -H, -OH, -CH₃, or -CH₂-CH₃.


15 15. The method of Claim 14, wherein the composition further comprises an epoxide hydrolase inhibitor.

20 16. The method of claim 14, wherein the compound is selected from the group of compounds shown in Figure 4.

5 17. A method of treating undesired angiogenesis in a human or animal comprising the step of administering to the human or animal with the undesired angiogenesis an effective amount of a compound selected from the group consisting of the following compounds:



10 where X is R_6 as defined above, or X is




15 and R_{25} and R_{26} are, independently, -OH, -H, or -NH₂.

20 18. The method of claim 17, wherein the compound is selected from the group consisting of the compounds in Figure 5.

25 19. The method of Claim 17, wherein the composition further comprises an epoxide hydrolase inhibitor.

5 20. A method of treating undesired angiogenesis in a human or animal comprising the steps of administering to the human or animal with the undesired angiogenesis a composition comprising an effective amount of an angiogenesis-inhibiting compound selected from the group consisting of the following compounds:



10 wherein compounds of structure (I), wherein R is selected from the group consisting of hydrogen, alkyl radicals of 1 to 6 carbon atoms, the phenyl radical, and the benzyl radical; and wherein R' is selected from the group consisting of the phthalimido radical and the succinimido radical and of structure (II), wherein X is CH₂ or C=O; R'' is H, -CH₂CH₃, -C₆H₅, -CH₂C₆H₅, -CH₂CH=CH₂, or structure (a) and hydrolysis products of the compounds wherein R'' is H and the piperidino ring or both the piperidino and the imido ring are hydrolyzed.

15

20

5 21. A method of treating undesired angiogenesis in a human or animal comprising the step of administering to the human or animal with the undesired angiogenesis a composition comprising an effective amount of a teratogenic compound that is anti-angiogenic in a pharmaceutically acceptable carrier.

10 22. A method of treating undesired angiogenesis in a human or animal comprising the step of administering to the human or animal with the undesired angiogenesis a composition comprising an effective amount of an angiogenesis inhibitor containing an epoxide group and an effective amount of an epoxide hydrolase inhibitor.

15 23. A method of treating a human or animal that has toxic concentrations of TNF- α comprising the step of administering to the human or animal that has toxic concentrations of TNF- α an effective amount of an angiogenesis inhibitor containing an epoxide group.

20 24. The method of Claim 24, wherein the composition further contains an effective amount of an epoxide hydrolase inhibitor.

25

Add B1